Freeline Therapeutics Holdings plc Quarterly Operating Income (Loss) in USD from Q1 2020 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Freeline Therapeutics Holdings plc quarterly/annual Operating Income (Loss) history and growth rate from Q1 2020 to Q1 2023.
  • Freeline Therapeutics Holdings plc Operating Income (Loss) for the quarter ending March 31, 2023 was -$20.1M, a 28.7% increase year-over-year.
  • Freeline Therapeutics Holdings plc annual Operating Income (Loss) for 2022 was -$98.4M, a 30.9% increase from 2021.
  • Freeline Therapeutics Holdings plc annual Operating Income (Loss) for 2021 was -$142M, a 39% decline from 2020.
  • Freeline Therapeutics Holdings plc annual Operating Income (Loss) for 2020 was -$102M, a 61% decline from 2019.
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2023 -$20.1M +$8.09M +28.7% Jan 1, 2023 Mar 31, 2023 6-K 2023-05-30
Q1 2022 -$28.2M +$5.77M +17% Jan 1, 2022 Mar 31, 2022 6-K 2023-05-30
Q1 2021 -$33.9M -$12.7M -60.2% Jan 1, 2021 Mar 31, 2021 6-K 2022-05-10
Q1 2020 -$21.2M Jan 1, 2020 Mar 31, 2020 6-K 2021-05-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.